Testing for programmed death receptor ligand (PD-L1) in metastatic non-small-cell lung cancer (NSCLC) patients; the Heart of England NHS Foundation Trust (HEFT) experience

导出原文传递

翻译打印收藏纠错

作者： Bancroft, H. ^[1] ; Kussaibati, R. ^[2] ; Hanna, T. ^[3] ; Langman, G. ^[4] ; Baijal, S. ^[5]

作者单位： Heart England NHS Trust, Oncol, Birmingham, W Midlands, England ^[1] Heart England NHS Fdn Trust, Thorac Surg Res, Birmingham, W Midlands, England ^[2] Heart England NHS Fdn Trust, Oncol, Birmingham, W Midlands, England ^[3] Univ Birmingham, Sch Med, TT, Birmingham B15 2TT, W Midlands, England ^[4] Heart England NHS Trust, Cellular Pathol, Birmingham, W Midlands, England ^[5]

发布时间 2020-08-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Lung cancer

2017年103卷Suppl.1期

S37-S38页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Testing for programmed death receptor ligand (PD-L1) in metastatic non-small-cell lung cancer (NSCLC) patients; the Heart of England NHS Foundation Trust (HEFT) experience

Lung cancer

相似文献

Lung cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Testing for programmed death receptor ligand (PD-L1) in metastatic non-small-cell lung cancer (NSCLC) patients; the Heart of England NHS Foundation Trust (HEFT) experience

Lung cancer

相似文献

Lung cancer

相关期刊

检索历史清除